Integration of PARP-inhibitors in ovarian cancer therapy

Poly-ADP-ribose polymerase inhibitors (PARP-I) represent one of the most attractive and promising class of biological agents studied both in relapsed ovarian cancer (OC) and in the advanced setting. The availability of this new class of drugs has changed the clinical management of OC ensuring an unp...

Descripción completa

Detalles Bibliográficos
Autores principales: Pietragalla, Antonella, Ciccarone, Francesca, Nero, Camilla, Scambia, Giovanni, Lorusso, Domenica, Daniele, Gennaro
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Open Exploration 2020
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9400691/
https://www.ncbi.nlm.nih.gov/pubmed/36046198
http://dx.doi.org/10.37349/etat.2020.00011

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9400691/
https://www.ncbi.nlm.nih.gov/pubmed/36046198
http://dx.doi.org/10.37349/etat.2020.00011

Ejemplares similares